Point72 Asset Management
TCRT icon

Point72 Asset Management’s Alaunos Therapeutics TCRT Stock Holding History

Point72 Asset Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-6,667
Closed -$1.24M – 1725
2022
Q2 		$1.24M Hold
6,667
– – 0.01% 1028
2022
Q1 		$652K Hold
6,667
– – ﹤0.01% 1000
2021
Q4 		$1.09M Sell
6,667
-2,466
-27% -$542K ﹤0.01% 899
2021
Q3 		$2.49M Buy
+9,133
New +$2.79M 0.01% 765
2015
Q3 		– Sell
-265
Closed -$478K – 894
2015
Q2 		$478K Buy
+265
New +$411K ﹤0.01% 642

Other funds holding TCRT

MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

Point72 Asset Management's TCRT Position: Q3 2022 in Review

Point72 Asset Management sold out of Alaunos Therapeutics (TCRT) in Q3 2022, closing a stake of 6,667 shares — an estimated $1.24M sold.

Point72 Asset Management first reported a position in TCRT in Q2 2015 and held it in 5 quarters. The position peaked at $2.49M in Q3 2021. 125 funds tracked by Wall St. Rank hold TCRT as of Q3 2022.

  • Point72 Asset Management reported no remaining Alaunos Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Point72 Asset Management sold 6,667 Alaunos Therapeutics shares in Q3 2022, an estimated $1.24M.
  • Point72 Asset Management first reported a position in Alaunos Therapeutics in Q2 2015 and held it in 5 quarters.
  • Point72 Asset Management's Alaunos Therapeutics position peaked at $2.49M in Q3 2021.
  • 125 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q3 2022.

Based on Point72 Asset Management's 13F filing for Q3 2022, filed 14 Nov 2022.